Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Yes/No (Response of no = patient ineligible)~1. Patients who are 18 years or older with a clinical or genetic diagnosis of Peutz-Jeghers Syndrome.~2. Patient has one or more intestinal polyps ≥ 5mm in maximum diameter by contrast enhanced CT scan that is not clinically indicated for removal or is beyond the reach of a push endoscope.~3. Minimum of two weeks since any major surgery.~4. Patient has had colonoscopy within the past 24 months and did not have high-grade dysplasia or colorectal cancers.~5. WHO performance status £ 2~6. Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L, Hgb \> 9 g/dL~7. Adequate liver function as shown by: serum bilirubin ≤ 1.5 x upper limit of normal (ULN), and serum transaminases activity ≤ 2.5 x ULN.~8. Patients must be able to provide written informed consent.~Exclusion Criteria:~Yes/No (Response of yes = patient ineligible)~1. Prior treatment with any investigational drug within the preceding 4 weeks~2. Chronic treatment with systemic steroids or another immunosuppressive agent~3. Patients should not receive immunization with attenuated live vaccines during study period or within one week of study entry~4. Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases~5. Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.~6. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:~   1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia~  2. Severely impaired lung function~  3. Uncontrolled diabetes as defined by fasting serum glucose \>1.5x ULN~  4. Any active (acute or chronic) or uncontrolled infection/ disorders.~  5. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy~  6. Liver disease such as cirrhosis, or severe hepatic impairment (Child-Pugh class C)~  7. A known history of HIV seropositivity~  8. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)~  9. Patients with an active, bleeding diathesis or on oral anti-vitamin K medication~7. Women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control throughout the trial and for 8 weeks after the last dose of study drug. (Women of childbearing potential must have a negative pregnancy test). Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study.~8. Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception during the study and for 9 weeks after the end of treatment.~9. Patients who have received treatment with an mTor inhibitor in the past 6 months.~10. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients~Patients who can not undergo FDG-PET are eligible to participate in this study for the purpose of the primary endpoint. Patient with the following will be excluded from FDG-PET piece of the study.~1. Patients cannot have a serum glucose level greater than 200 mg/dl for FDG-PET imaging~2. Patients who are too claustrophobic to undergo FDG-PET imaging~3. Patients who will require conscious sedation to undergo FDG-PET imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All participants enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues